Anaptysbio (ANAB) Free Cash Flow Growth (3y) (2019 - 2026)
Anaptysbio (ANAB) Free Cash Flow Growth (3y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -1.95% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -20.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 45.09% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.85% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -4.45% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 80.69% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 8.92% |
| 10 | Anaptysbio | 1.70 Bn | 1.41 Bn | - | -1.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.58% |
| Dec 31, 2025 | 122.78% |
| Sep 30, 2025 | -15.35% |
| Jun 30, 2025 | -18.71% |
| Mar 31, 2025 | 20.19% |
| Dec 31, 2024 | -38.09% |
| Sep 30, 2024 | -19.79% |
| Jun 30, 2024 | -64.44% |
| Mar 31, 2024 | -16.59% |
| Dec 31, 2023 | -43.08% |
| Sep 30, 2023 | -28.91% |
| Jun 30, 2023 | -9.14% |
| Mar 31, 2023 | -17.64% |
| Dec 31, 2022 | 12.08% |
| Sep 30, 2022 | 7.94% |
| Jun 30, 2022 | -16.21% |
| Mar 31, 2022 | -8.98% |
| Dec 31, 2021 | -26.54% |
| Sep 30, 2021 | 27.28% |
| Jun 30, 2021 | 43.06% |